Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers
Open Access
- 19 February 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (4) , 1416
Abstract
The management of non-small cell lung cancer (NSCLC) has transformed with the discovery of therapeutically tractable oncogenic drivers. In addition to activating driver mutations, gene fusions or rearrangements form a unique sub-class, with anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) targeted agents approved as the standard of care in the first-line setting for advanced disease. There are a number of emerging fusion drivers, however, including neurotrophin kinase (NTRK), rearrangement during transfection (RET), and neuregulin 1 (NRG1) for which there are evolving high-impact systemic treatment options. Brain metastases are highly prevalent in NSCLC patients, with molecularly selected populations such as epidermal growth factor receptor (EGFR) mutant and ALK-rearranged tumors particularly brain tropic. Accordingly, there exists a substantial body of research pertaining to the understanding of brain metastases in such populations. Little is known, however, on the molecular mechanisms of brain metastases in those with other targetable fusion drivers in NSCLC. This review encompasses key areas including the biological underpinnings of brain metastases in fusion-driven lung cancers, the intracranial efficacy of novel systemic therapies, and future directions required to optimize the control and prevention of brain metastases.Keywords
Funding Information
- International Association for the Study of Lung Cancer (IASLC Fellowship 2018-2020)
This publication has 99 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformationOncogene, 2011
- Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis TargetScience Translational Medicine, 2011
- The biology of brain metastases—translation to new therapiesNature Reviews Clinical Oncology, 2011
- Brain metastases as preventive and therapeutic targetsNature Reviews Cancer, 2011
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary TumorsClinical Cancer Research, 2009
- The phosphatidylinositol 3-kinase/akt signaling pathway in medullary thyroid cancerSurgery, 2008
- Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance SystemJournal of Clinical Oncology, 2004
- The trk family of tyrosine protein kinase receptorsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1991